Publications

 

Merrill J, et al. LSM 2018 – Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE.

View Publication

Ramsey-Goldman R, et al. LSM 2017 • Cell-bound complement activation products in SLE

View Publication

Buyon J, et al. LSM 2016 – Reduction in EC4d and anti-C1q antibodies associate with clinical improvement in SLE.

View Publication

Putterman C, et al. LSM. 2014. Cell_bound complement activation products in systemic lupus erythematosus.

View Publication

Wallace D, et al. LSM. 2016. Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products.

View Publication
 

AVISE CTD / AVISE Lupus / AVISE CB-CAPs

AVISE Lupus is indicated for the diagnosis of suspected SLE patients. AVISE CTD is indicated for differential diagnosis of autoimmune connective tissue diseases.

Clinical Validity

Erythrocyte complement receptor 1 (ECR1) and erythrocyte-bound C4d (EC4d) in the prediction of poor pregnancy outcomes in systemic lupus erythematosus (SLE).

Conklin J et al.

Lupus Science & Medicine 2022

A multianalyte assay panel with cell-bound complement activation products predicts transition of probable lupus to American College of Rheumatology-classified lupus.

Ramsey-Goldman R et al.

ACR Open Rheumatology 2021

Complement activation occurs in patients with probable systemic lupus erythematosus and may predict progression to ACR classified SLE.

Ramsey-Goldman R et al.

Arthritis & Rheumatology 2020

Cell-bound complement activation products associate with lupus severity in SLE.

Arriens C et al.

Lupus Science & Medicine 2020

Cell-bound complement activation products (CB-CAPs) have high sensitivity and specificity in pediatric-onset systemic lupus erythematosus and correlate with disease activity.

Hui-Yen J et al.

Lupus 2018

Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products.

Wallace D et al.

Lupus Science & Medicine 2016

Cell-bound complement activation products in systemic lupus erythematosus.

Putterman C et al.

Lupus Science & Medicine 2014

Clinical Utility

Complement activation products vs standard ANA testing: Treatment outcomes, diagnosis, and economic impact (CAPSTONE) in systemic lupus erythematosus.

O'Malley T et al.

Journal of Managed Care + Specialty Pharmacy 2022

A multianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus.

Alexander RV et al.

Lupus Science & Medicine 2021

Utility of the AVISE Connective Tissue Disease test in predicting lupus diagnosis and progression.

Liang E et al.

Lupus Science & Medicine 2020

Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE.

Wallace D et al.

Lupus Science & Medicine 2019

The AVISE Lupus test and cell-bound complement activation products aid the diagnosis of systemic lupus erythematosus.

Mossell J et al.

The Open Rheumatology Journal 2016

Health Economic Outcome Research

Evaluation of the economic benefit of earlier systemic lupus erythematosus (SLE) diagnosis using a multivariate assay panel (MAP).

Clarke A et al.

ACR Open Rheumatology 2020

Analytical Validity

Validation of multi-analyte panel with cell-bound complement activation products for systemic lupus erythematosus.

Dervieux T et al.

Journal of Immunological Methods 2017

Review Articles

A Review of Complement Activation in SLE.

Weinstein A et al.

Current Rheumatology Reports 2021

Cell-bound complement activation products in SLE.

Ramsey-Goldman R et al.

Lupus Science and Medicine 2017

Cell-bound complement activation products as lupus biomarkers: diagnosis, monitoring and stratification

Ahearn J et al.

Expert Review of Clinical Rheumatology 2017

Case Study

Probable systemic lupus erythematosus with cell-bound complement activation products (CB-CAPs).

Lamichhane D et al.

Lupus 2016

AVISE SLE Monitor

AVISE SLE Monitor is indicated for the ongoing assessment of SLE disease activity.

Clinical Validity

Antiphospholipid antibodies are persistently positive at high titers. Additive value of platelet-bound C4d.

Sciascia S et al.

Frontiers in Immunology 2022

Complement deposition, C4d, on platelets is associated with vascular events in systemic lupus erythematosus

Svenungsson E et al.

Rheumatology 2020

Platelet-bound C4d, low C3 and lupus anticoagulant associate with thrombosis in SLE.

Petri M et al.

Lupus Science & Medicine 2019

Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE.

Merrill JT et al.

Lupus Science & Medicine 2018

Performance characteristics of different anti-double-stranded DNA antibody assays in the monitoring of systemic lupus erythematosus.

Mahler M et al.

Journal of Immunology Research 2017

Reduction in erythrocyte-bound complement activation products and titers of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus.

Buyon J et al.

Lupus Science & Medicine 2016

Anti-C1q antibodies in systemic lupus erythematosus

Orbai AM et al.

Lupus 2015

Relation of platelet C4d with all-cause mortality and ischemic stroke in patients with systemic lupus erythematosus.

Kao AH et al.

Transitional Stroke Research 2014

Anti-C1q antibodies have a higher correlation with flares of lupus nephritis than other serum markers.

Akhter E et al.

Lupus 2012

Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus.

Kao A et al.

Arthritis & Rheumatology 2010

Erythrocyte C4d and Complement Receptor 1 in Systemic Lupus Erythematosus.

Singh V A et al.

The Journal of Rheumatology 2008

AVISE MTX

Avise MTX is indicated for RA patients receiving Methotrexate therapy as an objective measure of therapeutic exposure.

Clinical Validity

Differing contribution of methotrexate polyglutamates to adalimumab blood levels as compared with etanercept.

Dervieux T et al.

Annals of the Rheumatic Diseases 2019

Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: A 76-week prospective study

Takahashi C et al.

RMD Open 2017

Methotrexate polyglutamation in relation to infliximab pharmacokinetics in rheumatoid arthritis.

Dervieux T et al.

Annals of the Rheumatic Diseases 2013

Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis.

Dervieux T et al.

Rheumatology 2010

Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis.

Dervieux T et al.

Arthritis & Rheumatology 2006

Pharmacogentic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentered cross-sectional observation study

Dervieux T et al.

Annals of the Rheumatic Diseases 2005

Analytical Validity

Transition of methotrexate polyglutamate drug monitoring assay from venipuncture to capillary blood-based collection method in rheumatic diseases.

Brady K et al.

The Journal of Applied Laboratory Medicine 2019

Review Articles

Methotrexate: Optimizing the efficacy in rheumatoid arthritis. therapeutic advances in musculoskeletal disease.

Braun J et al.

Therapeutic Advances in Musculoskeletal Disease 2011

Toward a better understanding of methotrexate.

Kremer J et al.

Arthritis & Rheumatology 2004

AVISE HCQ

AVISE HCQ is indicated for SLE patients receiving Hydroxychloroquine therapy as an objective measure of drug exposure.

Clinical Validity

Interpreting hydroxychloroquine blood levels for medication non-adherence: a pharmacokinetic study.

Balevic S et al.

Lupus Science & Medicine 2024

Hydroxychloroquine blood levels predict hydroxychloroquine retinopathy.

Petri M et al.

Arthritis & Rheumatology 2020

A prospective international study on adherence to treatment in 305 patients with flaring SLE: Assessment by drug levels and self-administered questionnaires.

Costedoat-Chalumeau N et al.

Clinical Pharmacology and Therapeutics 2019

Hydroxychloroquine in systemic lupus erythematosus: Results of a French multicentre controlled trial (PLUS Study).

Costedoat-Chalumeau N et al.

Annals of the Rheumatic Diseases 2013

Analytical Validity

Capillary blood collected on volumetric absorptive microsampling (VAMS) device for monitoring hydroxychloroquine in rheumatoid arthritis patients.

Qu Y et al.

Journal of Pharmaceutical and Biomedical Analysis 2017

AVISE HCQ Review Articles

Hydroxychloroquine blood levels in systemic lupus erythematosus: Clarifying dosing controversies and improving adherence.

Durcan L et al.

The Journal of Rheumatology 2015

Anti-Carbamylated Protein Antibodies (Anti-CarP)

Reevaluating serologic markers of poor prognostic factors in rheumatoid arthritis.

Weinstein A et al.

The Journal of Rheumatology 2019

Association of the presence of anti-carbamylated protein antibodies in early arthritis with a poorer clinical and radiologic outcome: Data from the French ESPOIR cohort.

Truchetet ME et al.

Arthritis & Rheumatology 2017

Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage.

Shi J et al.

PNAS 2011

Selected Abstracts

Association of HCQ blood levels with Type 1 and 2 SLE activity

Sun K et al.

Arthritis & Rheumatology 2021

Cell-bound Complement Activation Products (CB-CAPs) predicts Type 1 SLE activity

Rogers J et al.

Arthritis & Rheumatology 2021

The incremental clinical utility of a multianalyte assay panel with cell-bound complement activation products versus a traditional ANA testing strategy for the diagnosis and treatment of SLE.

O'Malley T et al.

Arthritis & Rheumatology 2021

Multianalyte assay panel with cell-bound complement activation products demonstrates Clinical utility for the diagnosis and treatment of systemic lupus erythematosus role of platelet C4d in thrombosis and lupus nephritis.

Alexander R et al.

Arthritis & Rheumatology 2021

Role of platelet C4d in thrombosis and lupus nephritis.

Petri M et al.

Arthritis & Rheumatology 2020

Platelet-bound C4d is associated with an increased risk of arterial and venous thromboses in SLE.

Gartshteyn Y et al.

Arthritis & Rheumatology 2020

Agreement of hydroxychloroquine blood levels between a university and commercial laboratory.

Petri M et al.

Arthritis & Rheumatology 2020

Enhanced methotrexate polyglutamation in Japanese as compared to Caucasian rheumatoid arthritis patients starting methotrexate.

Dervieux T et al.

Arthritis & Rheumatology 2019

Diagnostic performances of antibodies against carbamylated proteins in U.S. rheumatoid arthritis and other autoimmune rheumatic diseases.

Shi J et al.

Arthritis & Rheumatology 2018

Complement activation in peripheral blood in relation to lupus, antiphospholipid and rheumatoid arthritis autoantibodies: Insights from clinical laboratory evaluations.

Dervieux T et al.

Arthritis & Rheumatology 2017

Cell-bound complement activation products distinguish systemic lupus erythematosus from other diseases among patients with high antinuclear antibody titers and normal complement.

Wallace D et al.

Arthritis & Rheumatology 2017